Spondyloarthritis and HIV infection, features of course and treatment
https://doi.org/10.24884/1609-2201-2025-104-1-22-31
Abstract
HIV infection is a very common disease, often associated with other pathologies, in particular rheumatological ones, such as spondyloarthritis. The presence of HIV infection can change the course of spondyloarthritis, and imposes certain limitations on their treatment. At the same time, progress in the treatment of HIV infection and spondyloarthritis has led to a change in the natural course of this combination of diseases and the emergence of new promising approaches to the treatment of patients with HIV and SpA. The presented work systematizes international experience in treating this cohort of patients, taking into account current trends.
About the Authors
K. S. Shashko
North-Western State Medical University named after I. I. Mechnikov
Russian Federation
Russian Federation
Ksenia S. Shashko, sixth year student of the Faculty of Medicine
41, Kirochnaya str., Saint Petersburg, 191015
I. Z. Gaydukova
North-Western State Medical University named after I. I. Mechnikov; St. Petersburg Clinical Rheumatology Hospital No. 25 named after V. A. Nasonova
Russian Federation
Russian Federation
Inna Z. Gaydukova, Dr. of Sci. (Med.), Deputy Director of the Research Institute of Rheumatology, Professor of the Department of Therapy, Rheumatology, Examination of Temporary Disability and Quality of Medical Care named after. E.E. Eichwald
41, Kirochnaya str., Saint Petersburg, 191015
References
1. Clinical recommendations. HIV infection in adults. 2020. URL: http://rushiv.ru/klinicheskie-rekomendatsii-vich-infektsiya-u-vzroslyh-2020 (accessed: 20.02.25). (In Russ.).
2. Statement of the Ministry of Health of Russia regarding a series of publications on the HIV situation. 2022. URL: https://minzdrav.gov.ru/news/2022/12/08/19630-zayavlenie-minzdrava-rossii-otnositelno-seriipublikatsiy-o-situatsii-s-vich (accessed: 20.02.25). (In Russ.)
3. Saigal R., Chakraborty A., Yadav R. N., Goyal L. K. Rheumatological Manifestations in HIV-Positive Patients: A Single-Center Study. Adv Ther. 2020;37(10):4336–45. https://doi.org/10.1007/s12325-020-01470-3.
4. Gridneva G. I., Belov B. S. Current issues in the management of patients with HIV infection and rheumatic diseases. Modern Rheumatology Journal. 2021;15(6):7–12. (In Russ.). https://doi.org/10.14412/1996-7012-2021-6-7-12.
5. Mallon E. Bunker C. B. HIV-associated psoriasis. AIDS Patient Care STDS. 2000;14:239–246.
6. Duvic M., Johnson T. M., Rapini R. P. et al. Acquired immunodeficiency syndrome-associated psoriasis and Reiter’s syndrome. Arch Dermatol. 1987; 123:1622–1632.
7. Erdes S. F., Badokin V. V., Bochkova A. G. et al. About the terminology of spondyloarthritis. Scientific and practical rheumatology. 2015;53(6):657–660. (In Russ.). https://doi.org/10.14412/1995-4484-2015-657-660.
8. Sellam J., Bouvard B., Masson C. et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Joint Bone Spine. 2007;74(2):197–200.
9. Bartke U., Venten I., Kreuter A. et al. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. Br J Dermatol. 2004;150(4):784–6. https://doi.org/10.1111/j.0007-0963.2004.05885.x.
10. Lindsey S. F., Weiss J., Lee E. S., Romanelli P. Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient. Journal of Drugs in Dermatology : JDD. 2014;13(7):869–871.
11. Motolese A., Ceccarelli M., Macca L. et al. Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease. Biomedicines. 2022;10(2):228.
12. Romita P., Foti C., Calianno G., Chiricozzi A. et al. Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast. Dermatologic therapy. 2022;35(8):e15610. https://doi.org/10.1111/dth.15610.
13. Liu Y., Foreman S. C., Joseph G. B. et al. Is treated HIV infection associated with knee cartilage degeneration and structural changes? A longitudinal study using data from the osteoarthritis initiative. BMC Musculoskelet Disord. 2019;20(1):190. https://doi.org/10.1186/ s12891-019-2573-5.
14. Tomi A. L., Sellam J., Lacombe K. et al. Increased prevalence and severity of radiographic hand osteoarthritis in patients with HIV-1 infection associated with metabolic syndrome: data from the cross-sectional METAFIB-OA study. Ann Rheum Dis. 2016;75(12):2101–7. https://doi.org/10.1136/annrheumdis-2016-209262.
15. Cepeda E. J., Williams F. M., Ishimori M. L. et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis. 2008;67(5):710–2. https://doi.org/10.1136/ard.2007.081513.
16. Paparizos V., Rallis E., Kirsten L., Kyriakis K. Ustekinumab for the treatment of HIV psoriasis. JDermatolog Treat. 2012;23(6):398–9. https:// doi.org/10.3109/09546634.2011.579085.
17. Saeki H., Ito T., Hayashi M. et al. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection. J Eur Acad Dermatol Venereol. 2015; 29:1653–1655.
18. Yang J. J., Tsai M. S., Sun H. Y. et al. Autoimmune diseases-related arthritis in HIV-infected patients in the era of highly active antiretroviral therapy. J Microbiol Immunol Infect. 2015;48(2):130–6. https://doi.org/10.1016/j.jmii.2013.08.002.
19. Altman E. M., Centeno L. V., Mahal M., Bielory L. AIDS-associated Reiter’s syndrome. Ann Allergy. 1994;72(4):307–16. PMID: 8154628.
20. Qian F., Yan Y., Huang J. et al. Use of ixekizumab in an HIV-positive patient with psoriatic arthritis. Int J STD AIDS. 2022;33(5):519–521. https://doi.org/10.1177/09564624221076289.
21. Bulbul R., Williams W. V., Schumacher H. R. Jr. Psoriatic arthritis. Diverse and sometimes highly destructive. Postgrad Med. 1995;97(4):97–9;103–6;108. PMID: 7716095.
22. Adizie T., Moots R. J., Hodkinson B. et al. Inflammatory arthritis in HIV positive patients: A practical guide. BMC Infect Dis. 2016;16:100. https://doi.org/10.1186/s12879-016-1389-2. PMID: 26932524; PMCID: PMC4774153.
23. Romero-Maté A., García-Donoso C., Córdoba-Guijarro S. EfÏcacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am J Clin Dermatol. 2007;8(3):143–55. https://doi.org/10.2165/00128071-200708030-00002. PMID: 17492843.
24. Manfreda V., Esposito M., Campione E. et al. Apremilast efÏcacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections. Postgrad Med. 2019;131(3):239–240. https://doi.org/10.1080/00325481. 2019.1575613.
25. Youssef P. P., Bertouch J. V., Jones P. D. Successful treatment of human immunodeficiency virus-associated Reiter’s syndrome with sulfasalazine. Arthritis Rheum. 1992;35:723–4. 26. Mahajan A., Tandon V., Verma S. Rheumatological manifestations in HIV infection. JIACM. 2006;7(2):136–44.
26. Schläpfer E., Fischer M., Ott P., Speck R. F. Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea. AIDS. 2003;17(11):1613–20.
27. Maganti R., Reveille J., Williams F. Therapy insight: the changing spectrum of rheumatic disease in HIV infection. Nat Clin Pract Rheumatol. 2008;4:428–38.
28. Yombi J. C., Maiter D., Belkhir L. et al. Iatrogenic Cushing’s syndrome and secondary adrenal insufÏciency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir. Clin Rheumatol. 2008;27 Suppl 2:S79–82.
29. Aboulafia D. M., Bundow D., Wilske K., Ochs U. I. Etanercept for the treatment of human immunodeficiency virus associated arthritis. Mayo Clin Proc. 2000;75:1093–8.
30. Sacchelli L., Patrizi A., Ferrara F., Bardazzi F. Apremilast as therapeutic option in a HIV positive patient with severe psoriasis. Dermatol Ther. 2018;31(6):e12719. https://doi.org/10.1111/dth.12719. PMID: 30358044.
31. Vílchez-Oya F., Orpinell Palacio L., Castillo Vilella M. et al. The use of secukinumab in an HIV-positive patient with axial spondyloarthritis: a case-based review. Clin Rheumatol. 2021;40(12):5111–5114. https://doi.org/10.1007/s10067-021-05922-1.
32. Gaylis N. Infliximab in the treatment of an HIV positive patient with Reiter’s syndrome. J Rheumatol. 2003;30(2):407–11. PMID: 12563704.
33. Gaylis N. B. Long-term follow-up of an HIV-infected patient with reactive arthritis treated with infliximab. J Clin Rheumatol. 2012;18(3):153–4. https:// doi.org/10.1097/RHU.0b013e31824e9151. PMID: 22426582.
34. Calabrese L. H., Zein N., Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004;63 Suppl 2(Suppl 2):ii18–ii24. https://doi.org/10.1136/ard.2004.028209. PMID: 15479865; PMCID: PMC1766782.
35. Carroll M. B., Fields J. H., Clerc P. G. Rheumatoid arthritis in patients with HIV: management challenges. Open Access Rheumatol. 2016;8:51–59. https://doi.org/10.2147/OARRR.S87312. PMID: 27843370; PMCID: PMC5098761.
36. Walker-Bone K., Doherty E., Sanyal K., Churchill D. Assessment and management of musculoskeletal disorders among patients living with HIV. Rheumatology (Oxford). 2017;56(10):1648–1661. https://doi.org/10.1093/rheumatology/kew418. PMID: 28013196; PMCID: PMC5483171.
37. Myers B., Thibodeaux Q., Reddy V. et al. Biologic Treatment of 4 HIVPositive Patients: A Case Series and Literature Review. J Psoriasis Psoriatic Arthritis. 2021;6(1):19–26. https://doi.org/10.1177/2475530320954279. PMID: 35784673; PMCID: PMC9249044.
38. Bourinbaiar A. S., Lee-Huang S. The non-steroidal anti-inflammatory drug, indomethacin, as an inhibitor of HIV replication. FEBS Lett. 1995;360(1):85–8. https://doi.org/10.1016/0014-5793(95)00057-g. PMID: 7875307.
39. Allegue F., Boixeda P., España A. et al. Síndrome de Reiter exacerbado por indometacina [Reiter’s syndrome exacerbated by indomethacin]. Med Cutan Ibero Lat Am. 1989;17(2):113–6. Spanish. PMID: 2666796.
40. Stein C. M., Davis P. Arthritis associated with HIV infection in Zimbabwe. J Rheumatol. 1996;23(3):506–11. PMID: 8832993.
41. Pettersen F. O., Torheim E. A., Dahm A. E. et al. An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. J Virol. 2011;85(13):6557–66. https://doi.org/10.1128/JVI.00073-11. PMID: 21490090; PMCID: PMC3126508.
42. Ulmer A., Müller M., Bertisch-Möllenhoff B., Frietsch B. Low dose prednisolone reduces CD4+ T cell loss in therapy-naive HIV-patients without antiretroviral therapy. Eur J Med Res. 2005;10(3):105–9. PMID: 15851376.
43. Ulmer A., Müller M., Bertisch-Möllenhoff B., Frietsch B. Low-dose prednisolone has a CD4-stabilizing effect in pre-treated HIV-patients during structured therapy interruptions (STI). Eur J Med Res. 2005;10(6):227–32. PMID: 16033711.
44. Masson C., Chennebault J. M., Leclech C. Is HIV infection contraindication to the use of methotrexate in psoriatic arthritis? J Rheumatol. 1995;22(11):2191. PMID: 8596175.
45. Mody G. M., Parke F. A., Reveille J. D. Articular manifestations of human immunodeficiency virus infection. Best Pract Res Clin Rheumatol. 2003;17(2):265–87. https://doi.org/10.1016/s1521-6942(03)00003-2. PMID: 12787525.
46. Tarr G., Makda M., Musenge E., Tikly M. Effect of human immunodeficiency virus infection on disease activity in rheumatoid arthritis: a retrospective study in South Africans. J Rheumatol. 2014;41(8):1645–9. https://doi.org/10.3899/jrheum.130896. PMID: 25028384.
47. Tourne L., Durez P., Van Vooren J. P. et al. Alleviation of HIV-associated psoriasis and psoriatic arthritis with cyclosporine. J Am Acad Dermatol. 1997;37(3 Pt 1):501–2. https://doi.org/10.1016/s0190-9622(97)70160-9. PMID: 9308575.
48. Galeazzi M., Giannitti C., Manganelli S. et al. Treatment of rheumatic diseases in patients with HCV and HIV infection. Autoimmun Rev. 2008;8(2):100–3. https://doi.org/10.1016/j.autrev.2008.07.009. PMID: 18694850.
49. Naovarat B. S., Salazar G., Ishimori M. et al. Biological treatment usage in patients with HIV and rheumatic disease, 2003-2021: long-term safety and follow-up. RMD Open. 2022;8(2):e002282. https://doi.org/10.1136/rmdopen-2022-002282. PMID: 35863862; PMCID: PMC9310260.
50. Foisy M. M., Yakiwchuk E. M., Chiu I., Singh A. E. Adrenal suppression and Cushing’s syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med. 2008;9(6):389–96. https:// doi.org/10.1111/j.1468-1293.2008.00579.x.
51. Kvale D., Ormaasen V., Kran A. M. et al. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment. AIDS. 2006;20(6):813–20. https://doi.org/10.1097/01.aids.0000218544.54586.f1. PMID: 16549964.
52. Prebensen C., Trøseid M., Ueland T. et al. Immune activation and HIVspecific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial. PLoS One. 2017;12(5):e0176527. https://doi.org/10.1371/journal.pone.0176527. PMID: 28464042; PMCID: PMC5413033.
Review
For citations:
Shashko K.S., Gaydukova I.Z. Spondyloarthritis and HIV infection, features of course and treatment. New St. Petersburg Medical Records. 2025;(1):22-31. (In Russ.) https://doi.org/10.24884/1609-2201-2025-104-1-22-31
Views:
40
Email this article 